Conditions: Atrophy Vaginal Diseases
Keywords: Menopausal symptoms Urogenital atrophy Vulvar and vaginal atrophy in menopausal women Vaginal atrophy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 180
Healthy volunteers: no

Brief summary:
The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Ospemifene (Dose 1) intervention 2: Ospemifene (Dose 2) intervention 3: Placebo
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: